Astronauts Print Human Organs in Space to Overcome Gravity's Collapse

Andrew Morgan, a physician and NASA astronaut, spent 272 days aboard the International Space Station in 2020, but his most consequential work happened in the microgravity laboratory orbiting 400 kilometers above Earth. There, he printed human heart tissue, cell by cell, using a 3D printer loaded with biotink—a biological ink designed to build living structures. The experiment was not science fiction. It was a deliberate test of whether the weightless environment of space could solve a problem that has plagued bioprinting on Earth: gravity itself.

Morgan's path to the ISS began in the field hospitals of Iraq and Afghanistan. As a frontline Army physician, he treated soldiers whose bodies had been torn apart by explosions—young men who lost limbs, who suffered catastrophic injuries that no surgeon could fully repair. Watching them heal slowly, incompletely, Morgan began to wonder: what if damaged tissue could simply be printed anew, using the patient's own cells? The possibility haunted him. If a wounded soldier could receive a new organ grown from his own biology, rejection would become nearly impossible. The body would recognize the transplant as itself.

The obstacle was gravity. When researchers tried to print tissue on Earth using a 3D bioprinter, the structure would collapse under its own weight as it formed. The cells needed support—a temporary biological scaffold—to hold them in place while they organized into functional tissue. This was especially true for hollow structures like the chambers of the heart. But in microgravity, that problem vanished. The tissue could form without support, layer upon layer, building complexity in the absence of downward force.

The Biofabrication Unit that Morgan used aboard the ISS had been launched in 2019 and upgraded by 2021. Developed by American companies Techshot and NScrypt, it was designed to print human cells into organ-like tissues. Morgan began with cardiac tissue of increasing thickness, but the team's ambition extended far beyond the heart. They wanted to print whole organs—kidneys, livers, lungs—that could be transplanted into patients waiting on lists that stretched across the world.

The scale of that need is staggering. Approximately one million people globally await kidney transplants alone. The World Health Organization estimates that only 130,000 organ transplants occur annually worldwide, meeting just 10 percent of demand. In the United States, 107,000 patients sit on transplant waiting lists. For those who do receive an organ from a donor, the price is a lifetime of immunosuppressant drugs to prevent their own immune system from rejecting the foreign tissue. A printed organ made from a patient's own cells would eliminate that burden.

Biotech companies around the world are racing toward this goal using different approaches. Most reprogramme a patient's cells using a Nobel Prize-winning technique developed a decade ago, converting them into stem cells—cells theoretically capable of becoming any tissue in the human body. With the right nutrients and signals, these stem cells can be coaxed into becoming the desired cell type, then suspended in hydrogel and printed layer by layer into functional living tissue. Itedale Redwan, the scientific lead at Cellink, the first company to commercialize biotink, estimates that fully functional printed organs suitable for human transplantation remain 10 to 15 years away. But the groundwork is accelerating. In 2018, researchers at Newcastle University printed the first human cornea. A team at Tel Aviv University produced a miniature heart from a cardiac patient's own cells. Scientists at Michigan State University printed a miniature human heart using a stem cell framework that mimicked fetal development, allowing them to create all the cell types and complex structures a beating heart requires.

Yet the heart, for all its symbolic weight, is relatively simple—chambers surrounded by muscle. The real challenge lies ahead: kidneys and livers are vastly more complex, composed of many cell types interwoven with networks of blood vessels and nerves. Jennifer Lewis, a bioengineering professor at Harvard, has spent years experimenting with tissue printing. She speaks candidly about what remains unknown: how to recreate the complete function of an organ, the synchronized beating of the heart, the filtering capacity of the kidney. "The function of tissue is often not as mature when created in the laboratory compared to living tissue," she says. "It may be easy in science fiction, but for us it is a dream. Still, we can already see the paths for this to become reality in the next two decades."

The cost of printing organs in space is prohibitive—the Biofabrication Unit alone cost seven million dollars, with additional expenses for launching materials and returning printed tissues safely to Earth. This has spurred research into whether microgravity conditions can be replicated on the ground. A Russian medical company, 3D Bioprinting Solutions, has developed a system using magnetic fields to levitate tissue as it forms. But even as scientists work to bring the technology home, some envision a different future: bioprinters installed in low Earth orbit, continuously producing increasingly complex human tissues in the weightless environment, eventually sustaining human missions to the Moon and Mars, where organ donors will be impossibly scarce and food production will demand the same cellular engineering.

Yet the prospect of printed organs raises questions that extend far beyond medicine. Steve Morris, chief executive of BioLife4D, has received emails calling his company "incarnate demons" for pursuing life extension. Others ask darker questions: If a parent could print a larger, more efficient heart for a twelve-year-old athlete, why not? If evolution gave us one set of heart valves, should we print two? Ken Church, CEO of NScrypt, speaks from the particular urgency of the personal: his daughter was born with only one lung. She is twenty-seven now and healthy, but still breathing with half a lung. "If I can create a lung for my daughter while she is alive, I will be very happy," he says. His company is developing the next generation of bioprinters, using centrifugation and oxygen infusion instead of microgravity to prevent tissue death at the core. The line between saving a life and enhancing it, between medicine and something else entirely, will define the decades ahead.